EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

Contact Supplier

SPI Pharma has been solving formulation challenges using superior functional materials.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

1DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Sulanemadlin [inn], 6bgf28r54m, Sulanemadlin [usan], Alrn-6924, Unii-6bgf28r54m, 1451199-98-6

Molecular Formula

C₉₅H₁₄₀N₂₀O₂₃

Molecular Weight

1930.2 g/mol

InChI Key

VDLGAZDAHPLOIR-RLPDZDIMSA-N

FDA UNII

6BGF28R54M

Sulanemadlin is an orally available peptide inhibitor of both murine double minute 2 (MDM2) and murine double minute X (MDMX), with potential antineoplastic activity. Upon oral administration, sulanemadlin binds to both MDM2 and MDMX and interferes with their interaction with the transcriptional activation domain of the tumor suppressor protein p53. By preventing MDM2-p53 and MDMX-p53 interactions, p53 activity is restored, which leads to p53-mediated induction of tumor cell apoptosis. MDM2 and MDMX, negative regulators of p53 function, are often overexpressed in cancer cells.

1 2D Structure

Sulanemadlin

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

3-[(2S,5S,8S,11S,14S,17S,20S,24E,32R)-32-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-acetamido-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-20-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-amino-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]carbamoyl]-14-(3-amino-3-oxopropyl)-5-[(4-hydroxyphenyl)methyl]-8-(1H-indol-3-ylmethyl)-11,20,32-trimethyl-17-(2-methylpropyl)-3,6,9,12,15,18,33-heptaoxo-1,4,7,10,13,16,19-heptazacyclotritriacont-24-en-2-yl]propanoic acid

2.1.2 InChI

InChI=1S/C95H140N20O23/c1-50(2)44-69(106-60(13)117)88(133)113-76(59(12)116)91(136)111-72(46-61-30-24-23-25-31-61)90(135)115-95(15)43-29-22-20-18-16-17-19-21-28-42-94(14,92(137)105-58(11)82(127)103-56(9)81(126)102-55(8)80(125)101-54(7)79(124)100-53(6)78(123)99-52(5)77(97)122)114-89(134)70(45-51(3)4)108-84(129)67(38-40-74(96)119)107-83(128)57(10)104-86(131)73(48-63-49-98-66-33-27-26-32-65(63)66)110-87(132)71(47-62-34-36-64(118)37-35-62)109-85(130)68(112-93(95)138)39-41-75(120)121/h17,19,23-27,30-37,49-59,67-73,76,98,116,118H,16,18,20-22,28-29,38-48H2,1-15H3,(H2,96,119)(H2,97,122)(H,99,123)(H,100,124)(H,101,125)(H,102,126)(H,103,127)(H,104,131)(H,105,137)(H,106,117)(H,107,128)(H,108,129)(H,109,130)(H,110,132)(H,111,136)(H,112,138)(H,113,133)(H,114,134)(H,115,135)(H,120,121)/b19-17+/t52-,53+,54+,55+,56+,57+,58+,59-,67+,68+,69+,70+,71+,72+,73+,76+,94+,95-/m1/s1

2.1.3 InChI Key

VDLGAZDAHPLOIR-RLPDZDIMSA-N

2.2 Other Identifiers

2.2.1 UNII

6BGF28R54M

2.3 Synonyms

2.3.1 Depositor-Supplied Synonyms

1. Sulanemadlin [inn]

2. 6bgf28r54m

3. Sulanemadlin [usan]

4. Alrn-6924

5. Unii-6bgf28r54m

6. 1451199-98-6

7. Alrn6924

8. N-acetyl-l-leucyl-l-threonyl-l-phenylalanyl-cyclo(d-r8-l-glutamyl-ltyrosyl-ltryptophanyl-l-alanyl-l-glutaminyl-l-leucyl-l-s5)-l-alanyl-lalanyl-l-alanyl-l-alanyl-lalanyl-d-alanylamide

9. Sulanemadlin [usan:inn]

10. Alrn 6924

11. Who 11411

12. Sulanemadlin (usan/inn)

13. Alrn 6924 [who-dd]

14. Glxc-27604

15. Hy-p4210

16. Cs-0650265

17. D12399

18. C2.11,c2.4-[(4e)-undec-4-ene-1,11-diyl](n-acetyl-lleucyl-l-threonyl-l-phenylalanyl-l-alanyl-l-alpha-glutamyll-tyrosyl-l-tryptophyl-l-alanyl-l-glutaminyl-l-leucyl-d-alanyl-l-alanyl-l-alanyl-l-alanyl-l-alanyl-l-alanyl-d-alaninamide)

19. D-alaninamide, 42,112-(7e)-7-undecene-1,11-diyl-n-acetyl-l-leucyl-lthreonyl-l-phenylalanyl-l-alanyl-l-alpha-glutamyl-l-tyrosyl-l-tryptophyl-l-alanyl-l-glutaminyl-l-leucyl-d-alanyl-l-alanyl-l-alanyl-l-alanyl-l-alanyl-l-alanyl-

2.4 Create Date

2022-07-07

3 Chemical and Physical Properties

Molecular Formula	C₉₅H₁₄₀N₂₀O₂₃
Molecular Weight	1930.2 g/mol
XLogP3	3.6
Hydrogen Bond Donor Count	23
Hydrogen Bond Acceptor Count	23
Rotatable Bond Count	37
Exact Mass	g/mol
Monoisotopic Mass	g/mol
Topological Polar Surface Area	674
Heavy Atom Count	138
Formal Charge	0
Complexity	4220
Isotope Atom Count	0
Defined Atom Stereocenter Count	18
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	1
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1